Publication

Bleeding complications during anticoagulant treatment in patients with cancer

Kamphuisen, P. W. & Beyer-Westendorf, J., May-2014, In : Thrombosis Research. 133, Suppl. 2, p. S49-S55 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Kamphuisen, P. W., & Beyer-Westendorf, J. (2014). Bleeding complications during anticoagulant treatment in patients with cancer. Thrombosis Research, 133(Suppl. 2), S49-S55. https://doi.org/10.1016/S0049-3848(14)50009-6

Author

Kamphuisen, Pieter W. ; Beyer-Westendorf, Jan. / Bleeding complications during anticoagulant treatment in patients with cancer. In: Thrombosis Research. 2014 ; Vol. 133, No. Suppl. 2. pp. S49-S55.

Harvard

Kamphuisen, PW & Beyer-Westendorf, J 2014, 'Bleeding complications during anticoagulant treatment in patients with cancer', Thrombosis Research, vol. 133, no. Suppl. 2, pp. S49-S55. https://doi.org/10.1016/S0049-3848(14)50009-6

Standard

Bleeding complications during anticoagulant treatment in patients with cancer. / Kamphuisen, Pieter W.; Beyer-Westendorf, Jan.

In: Thrombosis Research, Vol. 133, No. Suppl. 2, 05.2014, p. S49-S55.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Kamphuisen PW, Beyer-Westendorf J. Bleeding complications during anticoagulant treatment in patients with cancer. Thrombosis Research. 2014 May;133(Suppl. 2):S49-S55. https://doi.org/10.1016/S0049-3848(14)50009-6


BibTeX

@article{f1244979ca2744019590ff472e31ca89,
title = "Bleeding complications during anticoagulant treatment in patients with cancer",
abstract = "Patients with cancer have an increased risk of bleeding complications, of which some are fatal. This risk is influenced by chemotherapy, cancer type and stage, thrombocytopenia, renal function, and previous bleeding. Since many cancer patients receive anticoagulant treatment for prophylaxis or treatment of venous thromboembolism (VTE), bleeding complications are a challenge in clinical practice. This review article focuses on the overall bleeding risk of cancer patients and the risk of major and clinically relevant bleeding associated with anticoagulant treatment, such as vitamin K antagonists, LMWH and the direct oral anticoagulants. It also describes strategies for individual risk assessments.",
keywords = "Anticoagulation, Bleeding, Cancer, Venous thromboembolism, MOLECULAR-WEIGHT HEPARIN, VENOUS THROMBOEMBOLISM PROPHYLAXIS, MEDICAL PATIENTS, CLINICAL-ONCOLOGY, AMERICAN-SOCIETY, UNFRACTIONATED HEPARIN, RECEIVING CHEMOTHERAPY, SECONDARY PREVENTION, ADVANCED MALIGNANCY, PANCREATIC-CANCER",
author = "Kamphuisen, {Pieter W.} and Jan Beyer-Westendorf",
note = "Copyright {\circledC} 2014 Elsevier Ltd. All rights reserved.",
year = "2014",
month = "5",
doi = "10.1016/S0049-3848(14)50009-6",
language = "English",
volume = "133",
pages = "S49--S55",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "PERGAMON-ELSEVIER SCIENCE LTD",
number = "Suppl. 2",

}

RIS

TY - JOUR

T1 - Bleeding complications during anticoagulant treatment in patients with cancer

AU - Kamphuisen, Pieter W.

AU - Beyer-Westendorf, Jan

N1 - Copyright © 2014 Elsevier Ltd. All rights reserved.

PY - 2014/5

Y1 - 2014/5

N2 - Patients with cancer have an increased risk of bleeding complications, of which some are fatal. This risk is influenced by chemotherapy, cancer type and stage, thrombocytopenia, renal function, and previous bleeding. Since many cancer patients receive anticoagulant treatment for prophylaxis or treatment of venous thromboembolism (VTE), bleeding complications are a challenge in clinical practice. This review article focuses on the overall bleeding risk of cancer patients and the risk of major and clinically relevant bleeding associated with anticoagulant treatment, such as vitamin K antagonists, LMWH and the direct oral anticoagulants. It also describes strategies for individual risk assessments.

AB - Patients with cancer have an increased risk of bleeding complications, of which some are fatal. This risk is influenced by chemotherapy, cancer type and stage, thrombocytopenia, renal function, and previous bleeding. Since many cancer patients receive anticoagulant treatment for prophylaxis or treatment of venous thromboembolism (VTE), bleeding complications are a challenge in clinical practice. This review article focuses on the overall bleeding risk of cancer patients and the risk of major and clinically relevant bleeding associated with anticoagulant treatment, such as vitamin K antagonists, LMWH and the direct oral anticoagulants. It also describes strategies for individual risk assessments.

KW - Anticoagulation

KW - Bleeding

KW - Cancer

KW - Venous thromboembolism

KW - MOLECULAR-WEIGHT HEPARIN

KW - VENOUS THROMBOEMBOLISM PROPHYLAXIS

KW - MEDICAL PATIENTS

KW - CLINICAL-ONCOLOGY

KW - AMERICAN-SOCIETY

KW - UNFRACTIONATED HEPARIN

KW - RECEIVING CHEMOTHERAPY

KW - SECONDARY PREVENTION

KW - ADVANCED MALIGNANCY

KW - PANCREATIC-CANCER

U2 - 10.1016/S0049-3848(14)50009-6

DO - 10.1016/S0049-3848(14)50009-6

M3 - Article

VL - 133

SP - S49-S55

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - Suppl. 2

ER -

ID: 16028633